The Medicare Bridge program is a temporary demonstration project running from July of this year through December of 2027 that provides people over 65 and certain disabled individuals access to select weight loss medications, including Zepbound (tirzepatide), Foundayo (orforglipron) and Wegovy (semaglutide)
By purchasing, you confirm compliance with all applicable laws and regulations.
Deciding between indefinite treatment, dose reduction to maintenance levels, or gradual discontinuation with transition to lifestyle-only maintenance requires individual assessment
The American Journal of Gastroenterology, 113 (1), 115123
When GIP receptors activate in fat tissue, they appear to promote what researchers call fat cell browning, a process where white adipose tissue takes on characteristics of metabolically active brown fat
Side effects are generally manageable with proper dietary adjustments and hydration